ClinicalTrials.gg
RecruitingNCT07242690Updated Nov 17, 2026

PET-CT Imaging With PCD-CT

An interventional study of PCD-CT and PET CT in Head and Neck Cancer (H&N), sponsored by Medical University of South Carolina. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Medical University of South Carolina · Not applicable, Interventional, and Other

How we know

Updated Nov 17, 2026Now RecruitingSite recruiting status changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Head and Neck Neoplasms by Medical University of South Carolina — 6 open to participants now, 6 under way, none of them phase 3. Head and Neck Neoplasms · Medical University of South Carolina.

Planned enrollment
10th of 15
20 · median 30
Started
2026
with 2 others
No phase
12 of 17
5 open now
Registered
16th of 17
by date

Among the 17 studies in Head and Neck Neoplasms by Medical University of South Carolina, this one is the 10th largest by planned enrollment of the 15 interventional ones that give a count, is one of 3 that started in 2026, is one of 12 with no phase, and was the 16th registered.

Head and Neck Neoplasms

2,718 studies on the registry are indexed under Head and Neck Neoplasms; 599 are open to participants now.

Browse Head and Neck Neoplasms studies →

Open to participants now

6 of the 17 studies in Head and Neck Neoplasms by Medical University of South Carolina are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 458 Head and Neck Neoplasms studies recruiting now, 350 (76%) set no upper age limit and 51 (11%) stop at 75 or younger; 22 take children under 18; 27 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Head and Neck Neoplasms by Medical University of South Carolina, or all of them as a file.
02

Study summary

This pilot study evaluates the clinical utility of photon counting detector computed tomography (PCD-CT) in PET-CT imaging for head and neck cancer. Twenty adult patients undergoing standard-of-care PET-CT will also receive PCD-CT imaging. The study compares image quality and diagnostic confidence between conventional energy-integrating detector CT (EID-CT) and PCD-CT for attenuation correction and anatomical imaging.

03

Conditions studied

  • Head and Neck Cancer (H&N)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • Scheduled for or completed standard-of-care PET-CT of head and neck within ≤30 days

Exclusion criteria

Exclusion Criteria:

  • Non-diagnostic PET-CT
  • Intervening therapy between scans
  • Iodinated contrast allergy
  • Renal insufficiency ( \< 45)
  • Pregnancy
  • Gross motion artifacts
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Single group
Masking
Single (Outcomes assessor)
Enrollment
20 participants (estimated)

Study arms

  • Other
    PET CT scan

    To compare the image quality of PET images constructed using non-contrast PCD-CT image data to PET images constructed using conventional standard-of-care non-contrast EID-CT image data by performing a quantitative analysis of measurable image quality parameters.

    Other: PCD-CT

  • Other
    PCD-CT

    To compare the subjective image quality of PET images constructed using non-contrast PCD-CT image data to PET images constructed using conventional standard-of-care non-contrast EID-CT image data by performing a qualitative analysis of diagnostic confidence as determined by board-certified radiologists/nuclear medicine physicians during image review.

    Other: PET CT

Interventions

  • OtherPCD-CT

    A direct qualitative comparison of the subjective PET image quality will be performed. Two blinded board-certified radiologists/nuclear medicine physicians will independently review PET images constructed using non-contrast PCD-CT data as well as PET images constructed using standard of care non-contrast EID-CT data in random order. Both raters will assess PET images subjectively regarding overall image quality using a five-point Likert scale. The rating will be defined as: (1) non-diagnostic - insufficient diagnostic confidence, (2) poor - low diagnostic confidence, (3) moderate - average diagnostic confidence; (4) good - high diagnostic confidence, and (5) excellent - full diagnostic confidence.

  • OtherPET CT

    To compare the subjective image quality of PET images constructed using non-contrast PCD-CT image data to PET images constructed using conventional standard-of-care non-contrast EID-CT image data by performing a qualitative analysis of diagnostic confidence as determined by board-certified radiologists/nuclear medicine physicians during image review.

06

What researchers measure

Primary outcomes

  1. improve PET image w/ non-contrast PCD-CT data

    We expect that the subjective PET image quality will be improved by using non-contrast PCD-CT data for construction resulting in higher diagnostic confidence; demonstrating a case for the integration of PCD-CT into standard of care clinical PET-CT imaging in the future. There will be no direct benefit to study participants and the outcome will not be directly reported to the treatment team or patient and will not impact treatment or care received.

    Time frame: 2 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Dec 2027, 13 months later.

Of 440 non-industry interventional studies with no phase under Head and Neck Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 71. This study's planned 13 months is below that.

Counting every sponsor, half of 458 studies reached it within 33 months; a quarter within 18 and three quarters within 70.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 17, 2026: start Sep 2026 → Nov 2026, primary completion Dec 2026 → Dec 2027 and completion Jan 2027 → Jan 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2025
First posted
Nov 21, 2025
StartEst.
Nov 2026was Sep 2026
Primary completionEst.
Dec 1, 2027was Dec 2026
CompletionEst.
Jan 1, 2028was Jan 2027
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Suspended→Recruiting Reason for stopping removed
changed Nov 17, 2026
Sites
Medical University of South Carolina is now Recruiting
Nov 17, 2026
Start date
Sep 2026→Nov 2026
Nov 17, 2026
Primary completion
Dec 1, 2026→Dec 1, 2027
Nov 17, 2026
Study completion
Jan 1, 2027→Jan 1, 2028
Nov 17, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Medical University of South Carolina · Charleston, United StatesContact added h•••@musc.edu · •••0519
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Suspended→Recruiting
    Why stopped Reason for stopping removed
    Medical University of South Carolina is now Recruiting
    Start date Sep 2026→Nov 2026
    Primary completion Dec 1, 2026→Dec 1, 2027
    Study completion Jan 1, 2027→Jan 1, 2028
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Medical University of South Carolina · Charleston, United StatesContact added h•••@musc.edu · •••0519
    + 1 other change: responsible party

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07242690
Responsible party
Kevin Horn (Assistant Professor-Faculty, Medical University of South Carolina) — Principal investigator
First posted
Nov 21, 2025
Start date
Nov 2026 (estimated)
Primary completion
Dec 1, 2027 (estimated)
Completion
Jan 1, 2028 (estimated)
Last update
Nov 17, 2026

Study contacts

Kevin Horn, PhD, MD
principal investigator · Medical University of South Carolina

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion